Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, ...

Novavax has successfully achieved U.S. BLA approval and completed both EU and U.S. marketing authorization transfers for Nuvaxovid to Sanofi in line with its CLA ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

Q3 2025 Earnings Call Transcript November 6, 2025 Novavax, Inc. misses on earnings expectations. Reported EPS is $-1.24654 ...

US marketing authorization for its Covid-19 vaccine, Nuvaxovid to Sanofi, enabling Sanofi to take full responsibility for commercial and regulatory activities in the US and fulfilling part of its ...

RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York Supreme Court's summary judgment in favor of RedHill against Kukbo Co. Ltd ...

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, ...

Gaithersburg-based Novavax raised its annual revenue forecast, banking on milestone payments from vaccine supply and licensing deals.

Novavax Inc (NVAX) focuses on innovation and partnerships amid financial hurdles, aiming for profitability by 2028.

Novavax NVAX incurred a loss of 62 cents per share in the third quarter of 2025, which was narrower than the Zacks Consensus ...

The 2025-2026 respiratory viral season is approaching.With it comes the familiar challenge of protecting our most vulnerable ...